Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk
- Chemoprevention is the use of preventive medications to reduce the risk of breast cancer for women who are at a high risk of developing the disease. Although the treatment has shown effectiveness in preventing cancer development, chemoprevention is notably underutilized even by women who are at a high risk of developing breast cancer.
- Researchers are interested in determining if better decision support mechanisms, such as interactive Web sites, can help to overcome some of the barriers to chemoprevention.
- To develop and test a prototype Web-based module that will provide decision support to women who are considering chemoprevention for breast cancer.
- Women 35 years of age and older who are at high risk for breast cancer and whose doctor has recommended chemoprevention (either Tamoxifen or Raloxifene), and who have no other history of cancer (apart from non-melanoma skin cancer or precancerous cervical lesions).
- Participants must have a working e-mail address and access to a computer with internet access and a telephone.
- Participants who are considering chemoprevention will be randomized to a Web-based decision support module or standard care online information resources.
- Participation lasts two months and involves using the online resources provided and filling out questionnaires two times during the study (at the beginning and the end).
The first time will be at the begin of the study.
- No medical treatments are offered as a part of this study
- Breast cancer chemoprevention has been notably underutilized.
- Barriers to integrating breast cancer risk reducing measures include: lack of time, low priority of risk reduction in comparison to treatment, the need to personalize risks and benefits of chemoprevention, and the need for resources/information necessary for women to make informed decisions.
- Access to quality decision support resources to facilitate making informed, preference-sensitive decisions about chemoprevention may provide a mechanism to overcome some of the current barriers to chemoprevention utilization.
- Develop and refine a web-based patient decision support module for high-risk women making a decision about breast cancer chemoprevention.
- Conduct a randomized study of TACHD decision support versus standard care online information support to evaluate the impact of the chemoprevention module of the TACHD decision support intervention.
- Women with no history of cancer other than cervical carcinoma in situ or non-melanoma skin cancer
- High risk for breast cancer based on at least one of the following:
- Gail score > 1.67
- History of atypical hyperplasia (either ductal or lobular)
- History of lobular carcinoma in situ
- Documentation of a deleterious BRCA1 or BRCA2 mutation
- Considering a decision about chemoprevention with tamoxifen or raloxifene
- Access to an IBM-compatible or MacIntosh personal computer with broadband Internet access
- Access to an email account
- Access to a telephone
- Aged 35 or older
- Able to communicate in English verbally and in writing
- The project will be guided by the Cognitive-Social Health Information Processing (CSHIP) model overall, and incorporate the Ottawa Decision Support. Framework (ODSF) in one consistent decision support process.
- Testing of the chemoprevention decision support module will be conducted in a two-group pre- post-test experimental design with 64 at-risk women identified through Fox Chase Risk Assessment Programs and the NCI Clinical Cancer Genetics Program (CCGP) at the National Naval Medical Center (NNMC).
- A process evaluation analysis will assess participants' experiences using TACHD.
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
High Risk for Breast Cancer
Web-Based Decision Support
National Cancer Institute (NCI), 9000 Rockville Pike
National Institutes of Health Clinical Center (CC)
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT00906321
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Decision Support Systems, Clinical
Computer-based information systems used to integrate clinical and patient information and provide support for decision-making in patient care.
Hamartoma Syndrome, Multiple
A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Decision Support Techniques
Mathematical or statistical procedures used as aids in making a decision. They are frequently used in medical decision-making.
Inflammatory Breast Neoplasms
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
RATIONALE: A Web-based tool may be helpful for women at high risk of breast cancer make decisions about chemoprevention. PURPOSE: This randomized clinical trial is studying a Web-based de...
The purpose of this study is to develop a web-based decision aid to help women at high risk for breast cancer make informed breast cancer prevention choices. These choices include chemopre...
RATIONALE: Evaluating a decision aid that describes the risks and benefits of taking tamoxifen citrate to prevent breast cancer may be helpful for women at increased risk of breast cancer....
The objective of the study is to evaluate how the use of OncoDoc2, a computerized guideline-based decision support system, could improve the compliance of multidisciplinary staff meeting d...
To enhance information transfer and decision making for women with breast cancer.
A UK collaborative 1-day pilot information and support forum facilitated by a national breast cancer charity and NHS cancer genetic counsellors, for women at high risk, BRCA 1/2 gene carriers and hereditary breast cancer.
HARRIS J. & WARD S. (2011) European Journal of Cancer Care A UK collaborative 1-day pilot information and support forum facilitated by a national breast cancer charity and NHS cancer genetic counsello...
BACKGROUND: Learning about personal risk can provide numerous benefits yet people sometimes opt to remain ignorant. PURPOSE: Two studies examined the role of perceived control, coping resources, and a...
Abstract Objectives This study is to identify an optimal cut-off for two-stage breast cancer screening making allowance for variation of the baseline incidence rate and utility values between sensitiv...
Recently, the HOXB13 gene has been shown to be a susceptibility gene for prostate cancer. HOXB13 is overexpressed in breast cancer tissues and HOXB13 expression in combination with low expression of I...
Women are using estrogens for many purposes, such as to prevent pregnancy or miscarriage, or to treat menopausal symptoms. Estrogens also have been used to treat breast cancer which seems puzzling, si...